

Carbohydrate-binding Agents Cause Deletions of Highly HIV GP120

Journal of Biological Chemistry

280, 41005-41014

DOI: [10.1074/jbc.m508801200](https://doi.org/10.1074/jbc.m508801200)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Potential antivirals and antiviral strategies against SARS coronavirus infections. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 291-302.	2.0	142
2	Insights into neutralizing antibodies and HIV Envelope. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 301-308.	1.5	1
3	Large-molecular-weight carbohydrate-binding agents as HIV entry inhibitors targeting glycoprotein gp120. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 355-360.	1.5	10
4	Inhibition of HIV entry by carbohydrate-binding proteins. <i>Antiviral Research</i> , 2006, 71, 237-247.	1.9	147
5	Therapeutic strategies towards HIV-1 infection in macrophages. <i>Antiviral Research</i> , 2006, 71, 293-300.	1.9	39
6	Mutational Pathways, Resistance Profile, and Side Effects of Cyanovirin Relative to Human Immunodeficiency Virus Type 1 Strains with N-Glycan Deletions in Their gp120 Envelopes. <i>Journal of Virology</i> , 2006, 80, 8411-8421.	1.5	93
7	Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. <i>Journal of Leukocyte Biology</i> , 2006, 80, 1103-1110.	1.5	44
8	Cyanovirin-N Inhibits Hepatitis C Virus Entry by Binding to Envelope Protein Glycans. <i>Journal of Biological Chemistry</i> , 2006, 281, 25177-25183.	1.6	153
9	Primary Structure and Carbohydrate Binding Specificity of a Potent Anti-HIV Lectin Isolated from the Filamentous Cyanobacterium <i>Oscillatoria agardhii</i> . <i>Journal of Biological Chemistry</i> , 2007, 282, 11021-11029.	1.6	103
10	Strict specificity for high-mannose type N-glycans and primary structure of a red alga <i>Eucheuma serra</i> lectin. <i>Glycobiology</i> , 2007, 17, 479-491.	1.3	60
11	Pradimicin A, a Carbohydrate-Binding Nonpeptidic Lead Compound for Treatment of Infections with Viruses with Highly Glycosylated Envelopes, Such as Human Immunodeficiency Virus. <i>Journal of Virology</i> , 2007, 81, 362-373.	1.5	99
12	The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 741-749.	1.3	56
13	Carbohydrate-Binding Agents: A Potential Future Cornerstone for the Chemotherapy of Enveloped Viruses?. <i>Antiviral Chemistry and Chemotherapy</i> , 2007, 18, 1-11.	0.3	94
14	Sialic Acid on Herpes Simplex Virus Type 1 Envelope Glycoproteins Is Required for Efficient Infection of Cells. <i>Journal of Virology</i> , 2007, 81, 3731-3739.	1.5	27
15	The value of natural products to future pharmaceutical discovery. <i>Natural Product Reports</i> , 2007, 24, 1225.	5.2	316
16	A new lectin from the sea worm <i>Serpula vermicularis</i> : Isolation, characterization and anti-HIV activity. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2007, 145, 184-193.	1.3	34
17	The α (1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120. <i>FEBS Letters</i> , 2007, 581, 2060-2064.	1.3	20
18	Microbicide drug candidates to prevent HIV infection. <i>Lancet</i> , The, 2007, 369, 787-797.	6.3	180

#	ARTICLE	IF	CITATIONS
19	Fifteen years of Env C2V3C3 evolution in six individuals infected clonally with human immunodeficiency virus type 1. <i>Journal of Medical Virology</i> , 2007, 79, 1629-1639.	2.5	6
20	Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. <i>Nature Reviews Microbiology</i> , 2007, 5, 583-597.	13.6	264
21	Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. <i>Antiviral Research</i> , 2007, 75, 179-187.	1.9	242
22	Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture. <i>Antiviral Research</i> , 2007, 76, 21-29.	1.9	52
23	Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. <i>Virology</i> , 2007, 360, 294-304.	1.1	40
24	The role of N-glycosylation sites on the CXCR4 receptor for CXCL-12 binding and signaling and X4 HIV-1 viral infectivity. <i>Virology</i> , 2007, 363, 280-287.	1.1	27
25	Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. <i>Virology</i> , 2007, 366, 40-50.	1.1	70
26	Electrochemical evaluation of lectin-sugar interaction on gold electrode modified with colloidal gold and polyvinyl butyral. <i>Colloids and Surfaces B: Biointerfaces</i> , 2008, 66, 13-19.	2.5	37
27	Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention. <i>Virology</i> , 2008, 382, 10-19.	1.1	31
28	Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 2802-2814.	1.2	67
29	Inhibition of Cell-to-Cell Transmission of Human T-Cell Lymphotropic Virus Type 1 In Vitro by Carbohydrate-Binding Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2771-2779.	1.4	12
30	Simian Immunodeficiency Virus Is Susceptible to Inhibition by Carbohydrate-Binding Agents in a Manner Similar to That of HIV: Implications for Further Preclinical Drug Development. <i>Molecular Pharmacology</i> , 2008, 74, 330-337.	1.0	11
31	Carbohydrates on HIV: mediators of immune evasion and targets for antiviral intervention. <i>Future HIV Therapy</i> , 2008, 2, 253-257.	0.5	1
32	Diffusion of Two Potential Anti-HIV Microbicides across Intact and De-Epithelialised, Human Vaginal Mucosa. <i>European Journal of Inflammation</i> , 2008, 6, 17-23.	0.2	1
33	Human Immunodeficiency Virus Type 1 Escape from Cyclotriazadisulfonamide-Induced CD4-Targeted Entry Inhibition Is Associated with Increased Neutralizing Antibody Susceptibility. <i>Journal of Virology</i> , 2009, 83, 9577-9583.	1.5	10
34	The Phthalocyanine Prototype Derivative Alcian Blue Is the First Synthetic Agent with Selective Anti-Human Immunodeficiency Virus Activity Due to Its gp120 Glycan-Binding Potential. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4852-4859.	1.4	11
35	Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. <i>Virology</i> , 2009, 387, 67-75.	1.1	64
36	Carbohydrate recognition by boronolactins, small molecules, and lectins. <i>Medicinal Research Reviews</i> , 2010, 30, 171-257.	5.0	262

#	ARTICLE	IF	CITATIONS
37	Spermicides, Microbicides and Antiviral Agents: Recent Advances in the Development of Novel Multi-Functional Compounds. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 1556-1567.	1.1	7
38	Involvement of Envelope-Glycoprotein Glycans in HIV-1 Biology and Infection. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 191-208.	1.0	14
39	A new chitin-binding lectin from rhizome of <i>Setcreasea purpurea</i> with antifungal, antiviral and apoptosis-inducing activities. <i>Process Biochemistry</i> , 2010, 45, 1477-1485.	1.8	28
40	Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. <i>Nature Structural and Molecular Biology</i> , 2010, 17, 608-613.	3.6	92
41	Pradimicin S, a Highly Soluble Nonpeptidic Small-Size Carbohydrate-Binding Antibiotic, Is an Anti-HIV Drug Lead for both Microbicidal and Systemic Use. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1425-1435.	1.4	46
42	Microvirin, a Novel α (1,2)-Mannose-specific Lectin Isolated from <i>Microcystis aeruginosa</i> , Has Anti-HIV-1 Activity Comparable with That of Cyanovirin-N but a Much Higher Safety Profile. <i>Journal of Biological Chemistry</i> , 2010, 285, 24845-24854.	1.6	108
43	Multivalent Benzoboroxole Functionalized Polymers as gp120 Glycan Targeted Microbicide Entry Inhibitors. <i>Molecular Pharmaceutics</i> , 2010, 7, 116-129.	2.3	59
44	Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions. <i>Journal of Virology</i> , 2010, 84, 11905-11915.	1.5	181
45	Conformational stability of peanut agglutinin using small angle X-ray scattering. <i>International Journal of Biological Macromolecules</i> , 2011, 48, 398-402.	3.6	6
46	Targeting HIV Entry through Interaction with Envelope Glycoprotein 120 (gp120): Synthesis and Antiviral Evaluation of 1,3,5-Triazines with Aromatic Amino Acids. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5335-5348.	2.9	33
47	Activity and Safety of Synthetic Lectins Based on Benzoboroxole-Functionalized Polymers for Inhibition of HIV Entry. <i>Molecular Pharmaceutics</i> , 2011, 8, 2465-2475.	2.3	77
48	Investigation of Griffithsin's Interactions with Human Cells Confirms Its Outstanding Safety and Efficacy Profile as a Microbicide Candidate. <i>PLoS ONE</i> , 2011, 6, e22635.	1.1	99
49	Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs). <i>Antiviral Research</i> , 2011, 90, 200-204.	1.9	17
50	Inhibition of α -glucosidase and α -amylase by diaryl derivatives of imidazole-thione and 1,2,4-triazole-thiol. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2596-2601.	2.6	43
51	Recombinant expression of <i>Polygonatum cyrtoneuma</i> lectin with anti-viral, apoptosis-inducing activities and preliminary crystallization. <i>Process Biochemistry</i> , 2011, 46, 533-542.	1.8	19
52	The Highly Conserved Glycan at Asparagine 260 of HIV-1 gp120 Is Indispensable for Viral Entry. <i>Journal of Biological Chemistry</i> , 2011, 286, 42900-42910.	1.6	28
54	The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response. <i>Viruses</i> , 2011, 3, 1909-1932.	1.5	89
55	<i>Pinellia pedatisecta</i> agglutinin interacts with the methylosome and induces cancer cell death. <i>Oncogenesis</i> , 2012, 1, e29-e29.	2.1	25

#	ARTICLE	IF	CITATIONS
56	Thioredoxin-1 and protein disulfide isomerase catalyze the reduction of similar disulfides in HIV gp120. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 556-562.	1.2	36
57	Carbohydrate Recognition by the Antiviral Lectin Cyanovirin-N. <i>Journal of the American Chemical Society</i> , 2012, 134, 19639-19651.	6.6	23
58	Molecular architecture and therapeutic potential of lectin mimics. <i>Advances in Carbohydrate Chemistry and Biochemistry</i> , 2012, 68, 1-58.	0.4	11
59	Potential of carbohydrate-binding agents as therapeutics against enveloped viruses. <i>Medicinal Research Reviews</i> , 2012, 32, 349-387.	5.0	71
60	Anti-tumor and anti-viral activities of <i>Galanthus nivalis</i> agglutinin (GNA)-related lectins. <i>Glycoconjugate Journal</i> , 2013, 30, 269-279.	1.4	34
61	How to use the monographs. , 2013, , 353-961.		0
62	Dengue virus therapeutic intervention strategies based on viral, vector and host factors involved in disease pathogenesis. , 2013, 137, 266-282.		38
63	Inhibition of Hepatitis C Virus by the Cyanobacterial Protein <i>Microcystis viridis</i> Lectin: Mechanistic Differences between the High-Mannose Specific Lectins MVL, CV-N, and GNA. <i>Molecular Pharmaceutics</i> , 2013, 10, 4590-4602.	2.3	43
64	INHIBITION OF NITRIC OXIDE PRODUCTION IN THE MACROPHAGE-LIKE RAW 264.7 CELL LINE BY PROTEIN FROM THE RHIZOMES OF ZINGIBERACEAE PLANTS. <i>Preparative Biochemistry and Biotechnology</i> , 2013, 43, 60-78.	1.0	11
65	Inhibition of infection and transmission of HIV-1 and lack of significant impact on the vaginal commensal lactobacilli by carbohydrate-binding agents. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2026-2037.	1.3	14
66	Neutralizing IgG at the Portal of Infection Mediates Protection against Vaginal Simian/Human Immunodeficiency Virus Challenge. <i>Journal of Virology</i> , 2013, 87, 11604-11616.	1.5	44
67	Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS. <i>HIV/AIDS - Research and Palliative Care</i> , 2013, 5, 295.	0.4	10
68	Prime-Boost Immunization of Rabbits with HIV-1 gp120 Elicits Potent Neutralization Activity against a Primary Viral Isolate. <i>PLoS ONE</i> , 2013, 8, e52732.	1.1	17
69	Surfactant Protein D Inhibits HIV-1 Infection of Target Cells via Interference with gp120-CD4 Interaction and Modulates Pro-Inflammatory Cytokine Production. <i>PLoS ONE</i> , 2014, 9, e102395.	1.1	40
70	HIV-1 and Its Resistance to Peptidic Carbohydrate-Binding Agents (CBAs): An Overview. <i>Molecules</i> , 2014, 19, 21085-21112.	1.7	6
71	The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents. <i>Retrovirology</i> , 2014, 11, 107.	0.9	8
72	Exposure of HIV-1 to a combination of two carbohydrate-binding agents markedly delays drug resistance development and selects for virus strains with compromised fitness. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 582-593.	1.3	9
73	Bitter-sweet symphony: glycan-lectin interactions in virus biology. <i>FEMS Microbiology Reviews</i> , 2014, 38, 598-632.	3.9	117

#	ARTICLE	IF	CITATIONS
74	Natural Antiviral Compounds. <i>Studies in Natural Products Chemistry</i> , 2014, 42, 195-228.	0.8	13
75	Targeting strategies for delivery of anti-HIV drugs. <i>Journal of Controlled Release</i> , 2014, 192, 271-283.	4.8	47
76	Broad anti-HIV activity of the <i>Oscillatoria agardhii</i> agglutinin homologue lectin family. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2746-2758.	1.3	39
77	The Roles of Direct Recognition by Animal Lectins in Antiviral Immunity and Viral Pathogenesis. <i>Molecules</i> , 2015, 20, 2272-2295.	1.7	47
78	The Evolution of HIV-1 Interactions with Coreceptors and Mannose C-Type Lectin Receptors. <i>Progress in Molecular Biology and Translational Science</i> , 2015, 129, 109-140.	0.9	6
79	NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral activity profiles. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1674-1685.	1.3	32
80	Exposure of <i>Trypanosoma brucei</i> to an N-acetylglucosamine-Binding Lectin Induces VSG Switching and Glycosylation Defects Resulting in Reduced Infectivity. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003612.	1.3	11
81	Hepatoprotective potential of antioxidant potent fraction from <i>Urtica dioica</i> Linn. (whole plant) in CCl 4 challenged rats. <i>Toxicology Reports</i> , 2015, 2, 1101-1110.	1.6	30
82	Algal lectins as promising biomolecules for biomedical research. <i>Critical Reviews in Microbiology</i> , 2015, 41, 77-88.	2.7	54
83	A Designed "Nested" Dimer of Cyanovirin-N Increases Antiviral Activity. <i>Viruses</i> , 2016, 8, 158.	1.5	5
84	Binding Site Geometry and Subdomain Valency Control Effects of Neutralizing Lectins on HIV-1 Viral Particles. <i>ACS Infectious Diseases</i> , 2016, 2, 882-891.	1.8	20
85	Layer-by-Layer Engineered Microbicide Drug Delivery System Targeting HIV-1 gp120: Physicochemical and Biological Properties. <i>Molecular Pharmaceutics</i> , 2017, 14, 3512-3527.	2.3	21
86	Surface Glycans: A Therapeutic Opportunity for Kinetoplastid Diseases. <i>Trends in Parasitology</i> , 2017, 33, 775-787.	1.5	3
87	Overview of the role of kinetoplastid surface carbohydrates in infection and host cell invasion: prospects for therapeutic intervention. <i>Parasitology</i> , 2019, 146, 1743-1754.	0.7	7
88	Complex-type N-glycans on VSV-G pseudotyped HIV exhibit "tough" sialic and "brittle" mannose self-adhesions. <i>Soft Matter</i> , 2019, 15, 4525-4540.	1.2	8
89	Mannobiose Grafting Shifts PEI Charge and Biphasic Dependence on pH. <i>Macromolecular Chemistry and Physics</i> , 2019, 220, 1800423.	1.1	9
90	Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	1.4	11
91	Overview of the Structure-Function Relationships of Mannose-Specific Lectins from Plants, Algae and Fungi. <i>International Journal of Molecular Sciences</i> , 2019, 20, 254.	1.8	48

#	ARTICLE	IF	CITATIONS
92	<i>In Vitro</i> Characterization of the Carbohydrate-Binding Agents HHA, GNA, and UDA as Inhibitors of Influenza A and B Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	8
93	A Simple Biomimetic Receptor Selectively Recognizing the GlcNAc 2 Disaccharide in Water. <i>Angewandte Chemie</i> , 2021, 133, 11268-11272.	1.6	5
94	A Simple Biomimetic Receptor Selectively Recognizing the GlcNAc 2 Disaccharide in Water. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 11168-11172.	7.2	14
95	35 Years in plant lectin research: a journey from basic science to applications in agriculture and medicine. <i>Glycoconjugate Journal</i> , 2022, 39, 83-97.	1.4	19
96	HIV-1 entry inhibitors as microbicides. , 2007, , 99-117.		2
97	The role of N -glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents. <i>Retrovirology</i> , 2014, 11, 107.	0.9	5
98	Anti-HIV lectins and current delivery strategies. <i>AIMS Molecular Science</i> , 2018, 5, 96-116.	0.3	5
100	Entry Inhibitors Directed Towards Glycoprotein gp120: An Overview on a Promising Target for HIV-1 Therapy. <i>Current Medicinal Chemistry</i> , 2013, 20, 751-771.	1.2	4
101	Protective Effect of <i>Urtica dioica</i> Seeds Extract in Experimental Chronic Aflatoxicosis in Broiler Chickens. <i>International Journal of Poultry Science</i> , 2021, 20, 256-269.	0.6	0
102	A novel plant lectin, NTL-125, interferes with SARS-CoV-2 interaction with hACE2. <i>Virus Research</i> , 2022, 315, 198768.	1.1	5
103	Nutritional and pharmacological importance of stinging nettle (<i>Urtica dioica</i> L.): A review. <i>Heliyon</i> , 2022, 8, e09717.	1.4	44
105	Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	7
106	Anti-human immunodeficiency virus-1 activity of MoMo30 protein isolated from the traditional African medicinal plant <i>Momordica balsamina</i> . <i>Virology Journal</i> , 2023, 20, .	1.4	1
107	Antiviral Lectins of the Plant Family Amaryllidaceae. <i>Revista Brasileira De Farmacognosia</i> , 0, , .	0.6	0